{"id":115724,"date":"2023-12-18T13:30:00","date_gmt":"2023-12-18T08:00:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=115724"},"modified":"2023-12-18T13:17:10","modified_gmt":"2023-12-18T07:47:10","slug":"pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/","title":{"rendered":"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet;  Are you holding it?"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-4240297295\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3486216766\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>With a market capitalisation of Rs. 57,849 crores, shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/LUPIN\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Lupin Ltd<\/a><\/strong> started Monday\u2019s trading session on a higher note at Rs. 1,265 compared to its previous close of Rs. 1,246.10. The shares hit a high of Rs. 1,288, gaining around 3 percent and are currently trading at Rs. 1,276.70 apiece.\u00a0<\/p><p>Such a positive movement in the share price was observed after the company in an exchange filing mentioned that they had received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg to market a generic equivalent of Januvia Tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharp and Dohme Corp. (Merck).&nbsp;<\/p><p>Furthermore, they mentioned that these products would be manufactured at the company\u2019s Pithampur facility in India.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-4176779019\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>In addition, the company mentioned that these tablets are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. These tablets had estimated annual sales of USD 5789.3 million in the U.S.&nbsp;<\/p><p>Looking at the company\u2019s financial statement, the revenue increased by 5 percent from Rs. 4,814 crores in the June quarter to Rs. 5,039 crores during the September quarter. On the other hand, the net profits increased by 9 percent from Rs. 453 crores to Rs. 495 crores during the same timeframe.&nbsp;<\/p><p>The company wants to launch Complex Generics in Regulated Markets by 2028 through 20 product launches in the areas of inhalation, injectables, Biosimilar and Novel Complex Products. It also aims to complete 3 biosimilar filings in regulated markets and launch 10 novel complex pipeline products in India.&nbsp;<\/p><p>The company gets revenue from across the globe, primarily they get 37 percent of the revenue from India, 32 percent from the USA, and the remaining 31 percent from other markets and APIs.&nbsp;<\/p><p>Headquartered in Mumbai, Lupin Ltd was incorporated in 1983. The company develops and commercializes a wide range of branded and generic formulations, APIs, and biotechnology products in over 100 markets in India, U.S., South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Middle East regions, and Europe.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written By Vaibhav Patil<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong><strong><strong><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/strong><\/strong><\/strong><\/p><div class=\"trade-content-10\" id=\"trade-781488395\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><div class=\"trade-after-content\" id=\"trade-290704041\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.&nbsp; With a market capitalisation of Rs. 57,849 crores, shares of Lupin Ltd started [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":98971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[12353,13166,6618,2383,9153,9151,774,776,770,9158,6616,9157,3047,11745,5890,3046,6617],"class_list":["post-115724","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-debt-free-pharma-stocks","tag-fundamentally-strong-pharma-stocks","tag-large-cap-pharma-stocks","tag-lupin","tag-lupin-gets-a-buy-call","tag-lupin-latest-news","tag-lupin-news","tag-lupin-products","tag-lupin-share","tag-multibagger-pharma-stock-2023","tag-pharma-stock","tag-pharma-stock-2023","tag-pharma-stocks","tag-pharma-stocks-2023","tag-pharma-stocks-latest-news","tag-pharma-stocks-to-buy","tag-pharma-stocks-to-buy-now"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it? - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it?\" \/>\n<meta property=\"og:description\" content=\"Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-18T08:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/\",\"name\":\"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it? - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"datePublished\":\"2023-12-18T08:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it? - Trade Brains Features","description":"Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it?","og_description":"Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-12-18T08:00:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/","name":"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it? - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","datePublished":"2023-12-18T08:00:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"Shares of this large-cap company jumped around 3 percent after receiving approval from the US FDA for its abbreviated new drug application (ANDA) for, Sitagliptin tablets. The shares have delivered more than 70 percent returns to its shareholders on a YTD basis.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-us-fda-approval-for-diabetes-tablet-are-you-holding-it\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 3% after receiving US FDA approval for diabetes tablet; Are you holding it?"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/115724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=115724"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/115724\/revisions"}],"predecessor-version":[{"id":115728,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/115724\/revisions\/115728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/98971"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=115724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=115724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=115724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}